GLP 1 News and Research

RSS

The relationship between intestinal microbiome dysbiosis and atherosclerosis

Researchers investigate the impact of intestinal microbiota dysbiosis on atherosclerotic cardiovascular disease incidence.

15 Mar 2023

Long-acting GIPRA inhibits feeding and lowers body weight in mice with diet-induced obesity

The hormone glucose-dependent insulinotropic polypeptide (GIP) is considered obesogenic. In contrast, GIP receptor agonists (GIPRAs) have shown reduced feeding and body weight in an obese mouse model. Therefore, the precise effects exerted by GIP and GIPRAs remain elusive.

14 Mar 2023

Injectable peptide used for type 2 diabetes shows potential for treating 'blinding' IIH headaches

Patients with 'blinding' headaches known as Idiopathic Intercranial Hypertension could be treated with an injectable peptide used for type 2 diabetes, a new trial has found.

13 Mar 2023

How gut microbiota control feelings of fullness after eating

A recent study discusses recent findings linking satiety to the gut microbiome.

7 Mar 2023

Are SGLT2 inhibitors the next blockbuster drug?

Recent clinical trials investigating the therapeutic potency of sodium-glucose cotransporter 2 inhibitors (SGLT2i) have highlighted that this drug is highly effective in treating patients with cardiovascular and renal diseases.

19 Feb 2023

Revised guidelines for diabetes care

A recent Diabetes Care journal paper summarized the latest recommendations offered to people with diabetes to improve their health and well-being.

15 Dec 2022

Patients complain some obesity care startups offer pills, and not much else

Many Americans turn to the latest big idea to lose weight — fad diets, fitness crazes, dodgy herbs and pills, bariatric surgery, just to name a few. They're rarely the magic solution people dream of.

15 Nov 2022

Is there a right time for eating?

In a recent study published in the journal Cell Metabolism, researchers assessed how calorie or energy intake (EI) time influences calorie distribution and all energy expenditure (EE) components, which, in turn, impact energy balance and weight loss in healthy obese people.

12 Sep 2022

Eating disorders could be treated by modulating gut microbiota

Researchers describe how the gut-brain axis facilitates communication between the gastrointestinal tract and brain to regulate food consumption behaviors.

17 Aug 2022

A low-energy, high FODMAP diet in prediabetes and diabetes?

Researchers summarize the available knowledge on FODMAPs and suggest that they can play a role in the prevention and treatment of diabetes.

10 Aug 2022

Researchers assess Alzheimer's disease risk and anti-diabetic drugs

In a new study, researchers assessed the genetic variation among targets of Alzheimer's disease risk and anti-diabetic drugs.

3 Aug 2022

Machine learning and proteomics predict cardiovascular risk more accurately

An innovative proteomics-based model that predicts the risk of cardiovascular events with higher accuracy than current clinical models.

10 Apr 2022

Diabetes and the mTOR pathway in COVID-19 patients

A new study discusses the possible etiopathogenetic mechanisms associated with diabetes that could enhance the severity of COVID-19.

6 Mar 2022

Researchers discover why patients suffering with hypertension also have diabetes

The long-standing enigma of why so many patients suffering with high blood pressure (known as hypertension) also have diabetes (high blood sugar) has finally been cracked by an international team led by the universities of Bristol, UK, and Auckland, New Zealand.

1 Feb 2022

Study examines the association of race and ethnicity with initiation of newer diabetes medications

Among patients with type 2 diabetes, minority racial/ethnic groups have higher rates of diabetes complications including cardiovascular disease, chronic kidney disease and hypoglycemia (low blood sugar).

25 Jan 2022

DPP4 protein: The connection between severe COVID-19 and diabetes

Researchers explore the relationship between DPP4 and diabetes targets in the management of COVID-19.

17 Jan 2022

Fewer than 1 in 5 U.S. adults with Type 2 diabetes meet targets to reduce heart disease risk

Fewer than 1 in 5 adults with Type 2 diabetes in the U.S. are meeting targets to reduce heart disease risk. Fortunately, available therapies can help when combined with new approaches that address social determinants of health and other barriers to care, according to a new American Heart Association scientific statement published today in the Association's flagship journal Circulation.

10 Jan 2022

Flexibility may maximize the potency of peptides used to treat Type 2 diabetes

A little wiggle room might be just what the doctor ordered. New research suggests that the peptides -; short chunks of protein -; used to treat Type 2 diabetes may be more effective if they're able to flexibly move back and forth between different shapes.

23 Dec 2021

New study shows inequities in the use of heart disease-protective diabetes drug

A medication typically used for treating diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RA), could also be used to prevent cardiovascular disease and major cardiovascular events, but a new study showed inequities in its use based on race, ethnicity, and socioeconomic status.

17 Dec 2021

Drugs and surgery show promise for reducing long-term effects of obesity-related hypertension

Weight-loss medications and surgical procedures show promise for reducing the long-term effects of high blood pressure (also called hypertension) in people who are overweight or have obesity, according to a new American Heart Association scientific statement published today in the Association's journal Hypertension.

20 Sep 2021